Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 2/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31715017 | 0.76 | MAPT (0.44) | ALDH1A1LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL175006 | 0.76 | SMN1; SMN2 (0.54) | ALDH1A1LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL8693735 | 0.72 | SMN1; SMN2 (0.41) | ALDH1A1LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL4577091 | 0.72 | ALDH1A1 (0.46) | ALDH1A1ELOVL1CRHBPCRHR2LMNA | |
| SCHEMBL8693064 | 0.72 | ALDH1A1 (0.52) | ALDH1A1CRHBPCRHR2LMNAHTT | |
| SCHEMBL20027638 | 0.71 | MAPK1 (0.60) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8693623 | 0.71 | ALDH1A1 (0.48) | ALDH1A1CRHBPCRHR2LMNAHTT | |
| SCHEMBL4576752 | 0.71 | POLB (0.43) | ALDH1A1ELOVL1CRHBPCRHR2LMNA | |
| SCHEMBL8693579 | 0.70 | ALDH1A1 (0.43) | ALDH1A1LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL8693881 | 0.70 | HTT (0.43) | ALDH1A1LMNAHTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| EP-1966150-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007073297-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1966150-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073297-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | GRPR, GABRB3, GABRB1 | ALDH1A1 1412/4885ELOVL1 3672/4885CRHBP 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.